Every family deserves to know sooner. Early detection means more time together, more birthdays, more ordinary moments that matter most.
Early Detection Advocates
Combining breath biomarkers and blood molecular fingerprinting into a single unified platform. No other company integrates these modalities with longitudinal AI analysis at this scale.
Partnerships with the world's leading academic medical centers and research institutions. Active VERITY Study. Real clinical evidence backing every claim.
40+ patents filed across breath diagnostics, molecular analysis, and AI/ML algorithms. A defensible moat that deepens with every data point collected.
Exclusive partnership with Molecular Testing Labs (MTL) — a CLIA/CAP-certified reference lab processing 100K+ tests per month across 70+ assays. Nationwide payor coverage without the capital burden of ownership.
Longitudinal data creates compounding intelligence. The more patients we see, the smarter the platform becomes. This is the flywheel that competitors cannot replicate.
We combine breath diagnostics, blood molecular fingerprinting, advanced laboratory infrastructure, and agentic AI to bring earlier insight to patients and clinicians.
Graphene nanosensor arrays detect 3,000+ VOCs from a 60-second breath sample. 90+% sensitivity for lung cancer. Clinically validated with leading academic medical center collaborations. No needles. No lab. Immediate results.
40+ Patents • MyBreathPrint®
Molecular fingerprinting detects cancer before symptoms from a simple blood draw. 7x more accurate than Exact Sciences' CancerGuard for breast cancer. Multi-center VERITY clinical trial active. FDA pathway: 12–15 months.
VERITY Study Active • OncodeAi™
Agentic AI unifies breath, blood, and EHR data into real-time clinical intelligence via MyWellnessQ. HIPAA-compliant, enterprise-grade platform designed for large patient populations.
Enterprise-Grade • MyWellnessQFour distinct diagnostic modalities converging into a single Health OS for comprehensive patient insight.
VocxiHealth MyBreathPrint®
Non-invasive VOC detection
Oncodea OncodeAi™
Molecular fingerprinting
Integrated Health OS
Molecular Testing Labs
NGS, PGx, iFOB
RealBusiness.AI
Intelligence layer
The current diagnostic paradigm fails patients at every stage. Person Health was built to change this.
Biopsies, scopes, and procedures with inherent patient risk and discomfort.
Results take 3 to 21 days, delaying critical treatment decisions.
$1,500 to $6,000 per test, creating financial barriers to care.
Unavailable in 60% of U.S. counties, widening health disparities.
71% of cancer deaths occur at Stage III/IV when detected too late.
The urgency: 9.4 million missed cancer screenings post-COVID. Early detection infrastructure cannot wait.
Behind every statistic is a person. A parent. A child. Person Health exists to change these numbers — one breath, one test, one life at a time.
The only platform combining breath + blood + lab infrastructure + AI — built on a scalable operating platform designed to support large patient populations.
Across sensors, chemistry, AI methods, and diagnostic workflows
Non-invasive breath screening delivers actionable results in under one minute
Research and clinical partner locations across leading health systems
Whether you are an investor, a health system, or a technology vendor, Person Health offers a clear path to partnership and impact.
Person Health is building the operating system for early disease detection. This is not a single-product company — it is a compounding diagnostic infrastructure play with clear revenue visibility, real patients, and a proven proof cycle. Every patient, every data point, every clinical partnership strengthens the platform's intelligence and defensibility.
$5M+ 2026 Revenue Visibility | $250B+ TAM | 4 Integrated Modalities | 40+ Patents
The world's leading health systems are already engaged. Person Health integrates into existing clinical workflows with minimal disruption and maximum patient impact.
Initial deployment targets emergency and time-sensitive clinical situations affecting 15–20% of hospital admissions where survival outcomes decline rapidly when treatment is delayed. Conservative modeling shows $7.5M–$14.5M of operational impact per 10,000 admissions.
Person Health is building an ecosystem. We are seeking technology partners, lab equipment suppliers, and service providers who want to be part of the next generation of healthcare infrastructure.
For too long, healthcare has been organized around institutions rather than individuals. Person Health exists to change this fundamental equation.
We are not building a diagnostic product. We are building infrastructure for early understanding and lifelong health stewardship.
We believe every person deserves to know their health story — early, clearly, and completely.
Origins: Person Health was born from a University of Minnesota spinout (VocxiHealth), combined with molecular fingerprinting innovation (Oncodea) and an exclusive strategic lab partnership with Molecular Testing Labs (MTL) — powered by the RealBusiness.AI intelligence layer.
Mission: We believe every person deserves access to early detection — regardless of where they live or what they can afford. That belief drives everything we build.
Leadership: Our team combines enterprise AI architecture (Thomas Sheehan, 30+ years, 50+ product launches), clinical execution at FDA scale (Randy Schiestl, former Head of Global Technology at Boston Scientific), deep scientific innovation (Greg Sherwood, 80+ patents; Ali Khammanivong, PhD), and healthcare commercialization expertise — backed by medical and scientific advisory boards spanning leading academic medical centers and medtech companies.
Tell us who you are and how we can work together. We respond to every inquiry within two business days.